Soluble CD14: Genomewide association analysis and relationship to cardiovascular risk and mortality in older adults

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 1, 2013, Pages 158-164

  Reiner, Alex P ^a   Lange, Ethan M ^b   Jenny, Nancy S ^d   Chaves, Paulo H M ^c   Ellis, Jaclyn ^b   Li, Jin ^b   Walston, Jeremy ^e   Lange, Leslie A ^b   Cushman, Mary ^d   Tracy, Russell P ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD14; coronary heart disease; glycosylphosphotidylinositol; mortality

Indexed keywords

BIOLOGICAL MARKER; CD14 PROTEIN; ENZYME; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALLELE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; BLACK BEAN APHID; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHROMOSOME 5Q; EUROPEAN AMERICAN; FEMALE; GENE LOCUS; GENOME; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; VASCULAR DISEASE;

AFRICAN AMERICANS; AGE FACTORS; AGED; ANTIGENS, CD14; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHROMOSOMES, HUMAN, PAIR 5; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HAPLOTYPES; HEXOSYLTRANSFERASES; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; LINEAR MODELS; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84871821878     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300421     Document Type: Article

References (41)

1. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol. 1988;141:547-552.
2. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431-1433.
3. Tobias PS, Ulevitch RJ. Lipopolysaccharide binding protein and CD14 in LPS dependent macrophage activation. Immunobiology. 1993;187:227-232.
4. Bazil V, Baudys M, Hilgert I, Stefanová I, Low MG, Zbrozek J, Horejsí V. Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol Immunol. 1989;26:657-662.
5. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol. 1991;147:1567-1574.
6. Durieux JJ, Vita N, Popescu O, Guette F, Calzada-Wack J, Munker R, Schmidt RE, Lupker J, Ferrara P, Ziegler-Heitbrock HW. The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol. 1994;24:2006-2012.
7. Bufler P, Stiegler G, Schuchmann M, Hess S, Krüger C, Stelter F, Eckerskorn C, Schütt C, Engelmann H. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur J Immunol. 1995;25:604-610.
8. Su GL, Dorko K, Strom SC, Nüssler AK, Wang SC. CD14 expression and production by human hepatocytes. J Hepatol. 1999;31:435-442.
9. Pan Z, Zhou L, Hetherington CJ, Zhang DE. Hepatocytes contribute to soluble CD14 production, and CD14 expression is differentially regulated in hepatocytes and monocytes. J Biol Chem. 2000;275:36430-36435.
10. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. J Immunol. 2004;172:4470-4479.
11. Pugin J, Schürer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA. 1993;90:2744-2748.
12. Juan TS, Kelley MJ, Johnson DA, Busse LA, Hailman E, Wright SD, Lichenstein HS. Soluble CD14 truncated at amino acid 152 binds lipopolysaccharide (LPS) and enables cellular response to LPS. J Biol Chem. 1995;270:1382-1387.
13. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res. 2005;11:225-229.
14. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol. 1999;20:976-983.
15. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, Vercelli D. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol. 2001;167:5838-5844.
16. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
17. O'Leary DH, Polak JF, Wolfson SK Jr, Bond MG, Bommer W, Sheth S, Psaty BM, Sharrett AR, Manolio TA. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke. 1991;22:1155-1163.
18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-575.
19. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, Schaid DJ. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered. 2003;55:56-65.
20. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998;19:61-109.
21. Hetherington CJ, Kingsley PD, Crocicchio F, Zhang P, Rabin MS, Palis J, Zhang DE. Characterization of human endotoxin lipopolysaccharide receptor CD14 expression in transgenic mice. J Immunol. 1999;162:503-509.
22. Raney BJ, Cline MS, Rosenbloom KR, et al. ENCODE whole-genome data in the UCSC genome browser (2011 update). Nucleic Acids Res. 2011;39:D871-D875.
23. Zhang DE, Hetherington CJ, Tan S, Dziennis SE, Gonzalez DA, Chen HM, Tenen DG. Sp1 is a critical factor for the monocytic specific expression of human CD14. J Biol Chem. 1994;269:11425-11434.
24. Hubacek JA, Rothe G, Pit'ha J, Skodová Z, Stanek V, Poledne R, Schmitz G. C(-260)-T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation. 1999;99:3218-3220.
25. Heesen M, Blomeke B, Schluter B, Heussen N, Rossaint R, Kunz D. Lack of association between the 260 C-T promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels. Intens Care Med. 2001;27:1770-1775.
26. Ito D, Murata M, Tanahashi N, Sato H, Sonoda A, Saito I, Watanabe K, Fukuuchi Y. Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke. 2000;31:2661-2664.
27. Ferrer-Admetlla A, Bosch E, Sikora M, Marquès-Bonet T, Ramírez-Soriano A, Muntasell A, Navarro A, Lazarus R, Calafell F, Bertranpetit J, Casals F. Balancing selection is the main force shaping the evolution of innate immunity genes. J Immunol. 2008;181:1315-1322.
28. Kinoshita T, Fujita M, Maeda Y. Biosynthesis, remodelling and functions of mammalian GPI-anchored proteins: recent progress. J Biochem. 2008;144:287-294.
29. González-Pérez A, López-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet. 2011;88:440-449.
30. Heid IM, Jackson AU, Randall JC, et al; MAGIC. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet. 2010;42:949-960.
31. Fernández-Real JM, Pérez del Pulgar S, Luche E, Moreno-Navarrete JM, Waget A, Serino M, Sorianello E, Sánchez-Pla A, Pontaque FC, Vendrell J, Chacón MR, Ricart W, Burcelin R, Zorzano A. CD14 modulates inflammation-driven insulin resistance. Diabetes. 2011;60:2179-2186.
32. Johnson GB, Riggs BL, Platt JL. A genetic basis for the "Adonis" phenotype of low adiposity and strong bones. FASEB J. 2004;18:1282-1284.
33. Risley P, Jerrard-Dunne P, Sitzer M, Buehler A, von Kegler S, Markus HS; Carotid Atherosclerosis Progression Study. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis Progression Study (CAPS). Stroke. 2003;34:600-604.
34. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Promoter polymorphism of the gene for CD14 receptor is not associated with sub-clinical carotid atherosclerosis in a community population. Eur J Cardiovasc Prev Rehabil. 2004;11:344-349.
35. Amar J, Ruidavets JB, Bal Dit Sollier C, Bongard V, Boccalon H, Chamontin B, Drouet L, Ferrières J. Soluble CD14 and aortic stiffness in a population-based study. J Hypertens. 2003;21:1869-1877.
36. Amar J, Ruidavets JB, Bal dit Sollier C, Bongard V, Boccalon H, Chamontin B, Drouet L, Ferrières J. CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. J Hypertens. 2004;22:1523-1528.
37. Morange PE, Tiret L, Saut N, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Juhan-Vague I; PRIME Study Group. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet. 2004;12:1041-1049.
38. Zhang HF, Zhong BL, Zhu WL, Xie SL, Qiu LX, Zhu LG, Wang Y, Lei L. CD14 C-260T gene polymorphism and ischemic heart disease susceptibility: a HuGE review and meta-analysis. Genet Med. 2009;11:403-408.
39. Mikuls TR, LeVan TD, Sayles H, Yu F, Caplan L, Cannon GW, Kerr GS, Reimold AM, Johnson DS, Thiele GM. Soluble CD14 and CD14 polymorphisms in rheumatoid arthritis. J Rheumatol. 2011;38:2509-2516.
40. Landmann R, Zimmerli W, Sansano S, Link S, Hahn A, Glauser MP, Calandra T. Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis. 1995;171:639-644.
41. Haziot A, Ferrero E, Köntgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity. 1996;4:407-414.